Jeil Pharmaceutical Co Ltd (271980) — Capital Reinvestment Ratio
Latest as of September 2025:
0.27x
Jeil Pharmaceutical Co Ltd (271980) has a Capital Reinvestment Ratio of 0.27x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩13.23 Billion) in capital expenditures (₩3.55 Billion). See 271980 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.27x
Capex / Operating Cash Flow
Operating Cash Flow
₩13.23 Billion
KRW
Capital Expenditures
₩3.55 Billion
KRW
Data as of
Sep 2025
Most recent filing
Jeil Pharmaceutical Co Ltd Capital Reinvestment Ratio (2018–2024)
This chart tracks Jeil Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Jeil Pharmaceutical Co Ltd (2018–2024)
Year-by-year Capital Reinvestment Ratio for Jeil Pharmaceutical Co Ltd from 2018 to 2024. For live market cap and broader valuation context, see 271980 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.06x | ₩3.21 Billion | ₩6.61 Billion | ▲ +635.6% |
| 2021 | 0.28x | ₩19.10 Billion | ₩5.34 Billion | ▲ +646.2% |
| 2019 | 0.04x | ₩28.96 Billion | ₩1.09 Billion | ▼ -92.2% |
| 2018 | 0.48x | ₩21.45 Billion | ₩10.29 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow